Inloggen

Login
 
Wachtwoord vergeten?

Aandeel Pharming Group AEX:PHARM, NL0010391025

  • 1,189 30 nov 2020 17:44
  • +0,050 (+4,35%) Dagrange 1,151 - 1,236
  • 24.819.484 Gem. (3M) 6,9M

BE AFRAID CINRYZE, BE VERY AFRAID; PROPHYLAXIS STUDY NAILS IT

12 Posts
| Omlaag ↓
  1. papaji 30 juli 2016 09:45
    Pharming put up a major win, in our belief, with statistically significant data from the Phase II study using Ruconest in the HAE prophylaxis setting. The company will now look to the FDA/EMA for guidance on the path to label expansion beyond the acute setting. We maintain our Buy rating and $1.84 target.

    Event
    Pharming announced the Ruconest Phase II prophylaxis study met its primary endpoint in significantly reducing HAE attacks. This study was a randomized, double-blind, placebo-controlled study, which enrolled 32 patients with HAE with at least four attacks per month. The primary endpoint was met in statistically significant fashion (p<0.0001) and was a >50% reduction in the number of attacks compared to placebo over 28 days (details below). Twice weekly and once weekly dosing were compared to placebo. Recall that Ruconest is partnered 50/50 with U.S. partner Valeant (VRX-NC).

    Impact
    This is a major win for Pharming and Ruconest, in our belief. The clinical data are strong and we believe that the data point to potential superiority over Shire's (SHPG-NC) on two fronts: 1) the patient population in the Ruconest study appeared more severe with at least four attacks per month at baseline compared with Cinryze's two (we note though that the Cinryze study was a 12-week study) and 2) safety should represent the key differentiator as a recombinant protein compared to plasma based Cinryze. The risks around plasma based products continue, including thromboembolic events and bloodborne infections. Pharming and Valeant will now engage the FDA and EMA to discuss the path forward for Ruconest in the prophylaxis setting as the company continues to "block and tackle" in building its revenue and geographies in the acute setting. From a perception standpoint, we believe investors still have some trepidations, not on the strength of the data/product, but rather on the ongoing trials and tribulations at Valeant.

    Action
    We maintain our Buy rating and $1.84 price target. The company's strategy to expand geographies through collaborations and to develop therapies for rare diseases should bear fruit over the long term, in our opinion. Given the pricing power of orphan drugs and the expanding markets in these indications due to better diagnoses, we believe that Pharming is well-positioned for commercial success.

    above an extract from analyst roth coverage 28/july:
    www.pharming.com/wp-content/uploads/2...
  2. [verwijderd] 30 juli 2016 11:09
    quote:

    papaji schreef op 30 juli 2016 09:45:


    Pharming put up a major win, in our belief, with statistically significant data from the Phase II study using Ruconest in the HAE prophylaxis setting. The company will now look to the FDA/EMA for guidance on the path to label expansion beyond the acute setting. We maintain our Buy rating and $1.84 target.

    Event
    Pharming announced the Ruconest Phase II prophylaxis study met its primary endpoint in significantly reducing HAE attacks. This study was a randomized, double-blind, placebo-controlled study, which enrolled 32 patients with HAE with at least four attacks per month. The primary endpoint was met in statistically significant fashion (p<0.0001) and was a >50% reduction in the number of attacks compared to placebo over 28 days (details below). Twice weekly and once weekly dosing were compared to placebo. Recall that Ruconest is partnered 50/50 with U.S. partner Valeant (VRX-NC).

    Impact
    This is a major win for Pharming and Ruconest, in our belief. The clinical data are strong and we believe that the data point to potential superiority over Shire's (SHPG-NC) on two fronts: 1) the patient population in the Ruconest study appeared more severe with at least four attacks per month at baseline compared with Cinryze's two (we note though that the Cinryze study was a 12-week study) and 2) safety should represent the key differentiator as a recombinant protein compared to plasma based Cinryze. The risks around plasma based products continue, including thromboembolic events and bloodborne infections. Pharming and Valeant will now engage the FDA and EMA to discuss the path forward for Ruconest in the prophylaxis setting as the company continues to "block and tackle" in building its revenue and geographies in the acute setting. From a perception standpoint, we believe investors still have some trepidations, not on the strength of the data/product, but rather on the ongoing trials and tribulations at Valeant.

    Action
    We maintain our Buy rating and $1.84 price target. The company's strategy to expand geographies through collaborations and to develop therapies for rare diseases should bear fruit over the long term, in our opinion. Given the pricing power of orphan drugs and the expanding markets in these indications due to better diagnoses, we believe that Pharming is well-positioned for commercial success.

    above an extract from analyst roth coverage 28/july:
    www.pharming.com/wp-content/uploads/2...



    Een koersdoel in dollars?

    Roth heeft in het verleden al aangetoond weinig zorgvuldig te zijn. Ze flansen even snel een rapportje in elkaar en ach wat maakt het uit, we plakken er een met de valutakoers bewegend koersdoel aan vast.

    En geen enkele aandacht voor het financieringsvraagstuk dat eind dit jaar gaat spelen. Met € 21 miljoen in kas, € 10 miljoen halfjaarlijkse operationele cash burn en daarbovenop aflossing en rente is de bodem van de kas eind dit jaar in zicht.
12 Posts
|Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

Pharming Group Meer »

Koers 1,189   Verschil +0,05 (+4,35%)
Laag 1,151   Volume 24.819.484
Hoog 1,236   Gem. Volume 6.921.439
30 nov 2020 17:44
label premium

Omzetherstel bij Pharming

Het laatste advies leest u als IEX Premium-lid

Inloggen Ontdek Premium

Gerelateerde Video's

  1. video thumbnail

    Outlook Pharming

    7 juni 2018 16:58 - Vimeo

  2. video thumbnail

    Pharming: Groeiperspectieven

    13 maart 2018 22:16 - Vimeo

  3. video thumbnail

    Pharming kan verder omhoog

    27 oktober 2017 17:23 - Vimeo

  4. video thumbnail

    Arend Jan Kamp over Pharming

    26 oktober 2017 13:24 - Vimeo

 
Quotedata: Amsterdam realtime by Euronext, other realtime by Cboe Europe Ltd.   US stocks: by NYSE & Cboe BZX Exchange, 15min delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by Infront. Crypto data by Crypto Compare